Tweets
Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
The great debate
Next steps to develop RA prevention
Kevin Deane
“It’s time to move from disease modifying drugs to disease modifying therapeutic approaches”
#ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Advancing Telemedicine in Rheumatology
'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow
@RheumNow #ACR22
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
Pts w/ pre-existing rheumatic conditions 3.6 times likelier to new rheumatic disease features or worsening disease after starting ICI for melanoma, Abs 0756 #ACR22 @RheumNow https://t.co/s1f1QxmJzA https://t.co/6cKllBzqJn
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Osteoporotic fx in AS
Abstract #0388 #ACR22 @RheumNow
🦴2k adults in RISE, mean age 68y, 44% female, 76% white
🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI
🦴Men and women were equally likely to fracture
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Multiplex peripheral blood in 200+ ILD pts
Differences in IL-17 RD-ILD>IPF> IPAF
Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF
OR 0.4
Almost surprising considering known profibrotic role of IL-13 🧐
https://t.co/21UMq6w9hI
Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy.
@RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#ACR22 Advancing Telemedicine in Rheumatology
'60% prefer telemedicine for routine visits and review lab results'
https://t.co/HUgoocXodE
@RheumNow #ACR22
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
